US Stock MarketDetailed Quotes

CRSP CRISPR Therapeutics

Watchlist
  • 48.680
  • -1.160-2.33%
Close Dec 10 16:00 ET
  • 48.900
  • +0.220+0.45%
Post 20:01 ET
4.16BMarket Cap-17448P/E (TTM)

CRISPR Therapeutics Key Stats

Earnings

Revenue Breakdown

Financial Indicators

Income Statement

Balance Sheet

Cash Flow

Quarterly+Annual
YOY yoy
Hide blank lines yoy
(Q3)Sep 30, 2024
(Q2)Jun 30, 2024
(Q1)Mar 31, 2024
(FY)Dec 31, 2023
(Q4)Dec 31, 2023
(Q3)Sep 30, 2023
(Q2)Jun 30, 2023
(Q1)Mar 31, 2023
(FY)Dec 31, 2022
(Q4)Dec 31, 2022
Total revenue
0
0
0
84,762.39%370M
3,333,233.33%200M
0
44,203.80%70M
56,079.78%100M
-99.95%436K
-99.95%6K
Operating revenue
--0
--0
--0
84,762.39%370M
3,333,233.33%200M
--0
44,203.80%70M
56,079.78%100M
-99.95%436K
-99.95%6K
Cost of revenue
-52.38%11.15M
16.79%52.13M
11.31%46.97M
18.14%130.25M
193.13%20M
-39.73%23.42M
31.58%44.64M
37.68%42.19M
8.97%110.25M
-78.56%6.82M
Gross profit
52.38%-11.15M
-305.53%-52.13M
-181.24%-46.97M
318.32%239.75M
2,740.46%180M
39.58%-23.42M
175.12%25.36M
289.73%57.81M
-113.53%-109.81M
65.00%-6.82M
Operating expense
-9.19%98.98M
-17.79%99.13M
-23.45%93.62M
-17.94%462.29M
-11.47%110.42M
-24.11%108.99M
-19.34%120.59M
-15.95%122.3M
28.51%563.35M
-1.19%124.72M
Selling and administrative expenses
-4.77%17.42M
2.36%19.48M
-19.71%17.95M
-25.67%76.16M
-22.16%16.48M
-32.26%18.29M
-27.56%19.03M
-20.20%22.36M
2.78%102.46M
-10.60%21.17M
-General and administrative expense
-4.77%17.42M
2.36%19.48M
-19.71%17.95M
-25.67%76.16M
-22.16%16.48M
-32.26%18.29M
-27.56%19.03M
-20.20%22.36M
2.78%102.46M
-10.60%21.17M
Research and development costs
-9.41%82.16M
-21.06%80.17M
-23.78%76.17M
-16.10%387.33M
-8.12%95.14M
-22.23%90.7M
-17.58%101.56M
-15.48%99.94M
35.55%461.65M
0.45%103.56M
Other operating expenses
---602K
---517K
---504K
-58.27%-1.21M
----
----
----
----
59.51%-762K
--0
Operating profit
16.83%-110.13M
-58.85%-151.26M
-118.01%-140.59M
66.94%-222.54M
152.90%69.58M
27.40%-132.41M
48.04%-95.22M
63.35%-64.49M
-280.22%-673.16M
9.72%-131.54M
Net non-operating interest income expense
Other net income (expense)
21.25%25.06M
42.01%26.14M
94.00%24.72M
216.91%71.82M
74.04%20M
184.57%20.67M
419.36%18.41M
3,410.19%12.74M
277.49%22.66M
422.99%11.49M
Other non- operating income (expenses)
21.25%25.06M
42.01%26.14M
94.00%24.72M
216.91%71.82M
74.04%20M
184.57%20.67M
419.36%18.41M
3,410.19%12.74M
277.49%22.66M
422.99%11.49M
Income before tax
23.87%-85.07M
-62.88%-125.12M
-123.92%-115.87M
76.83%-150.72M
174.62%89.58M
36.19%-111.74M
57.26%-76.82M
70.53%-51.75M
-271.40%-650.5M
16.34%-120.05M
Income tax
112.62%876K
39.44%1.29M
-45.15%724K
988.62%2.89M
102.46%233K
171.65%412K
-84.91%923K
-63.41%1.32M
-117.38%-325K
-320.59%-9.48M
Net income
23.37%-85.94M
-62.60%-126.41M
-119.71%-116.59M
76.37%-153.61M
180.80%89.35M
35.75%-112.15M
58.17%-77.74M
70.39%-53.07M
-272.16%-650.18M
21.72%-110.58M
Net income continuous Operations
23.37%-85.94M
-62.60%-126.41M
-119.71%-116.59M
76.37%-153.61M
180.80%89.35M
35.75%-112.15M
58.17%-77.74M
70.39%-53.07M
-272.16%-650.18M
21.72%-110.58M
Minority interest income
Net income attributable to the parent company
23.37%-85.94M
-62.60%-126.41M
-119.71%-116.59M
76.37%-153.61M
180.80%89.35M
35.75%-112.15M
58.17%-77.74M
70.39%-53.07M
-272.16%-650.18M
21.72%-110.58M
Preferred stock dividends
Other preferred stock dividends
Net income attributable to common stockholders
23.37%-85.94M
-62.60%-126.41M
-119.71%-116.59M
76.37%-153.61M
180.80%89.35M
35.75%-112.15M
58.17%-77.74M
70.39%-53.07M
-272.16%-650.18M
21.72%-110.58M
Basic earnings per share
28.37%-1.01
-52.04%-1.49
-113.43%-1.43
76.79%-1.94
180.14%1.13
37.05%-1.41
59.17%-0.98
71.12%-0.67
-268.21%-8.36
23.37%-1.41
Diluted earnings per share
28.37%-1.01
-52.04%-1.49
-113.43%-1.43
76.79%-1.94
180.14%1.13
37.05%-1.41
59.17%-0.98
71.12%-0.67
-277.87%-8.36
23.37%-1.41
Dividend per share
Currency Unit
USD
USD
USD
USD
USD
USD
USD
USD
USD
USD
Accounting Standards
US-GAAP
US-GAAP
US-GAAP
US-GAAP
US-GAAP
US-GAAP
US-GAAP
US-GAAP
US-GAAP
US-GAAP
Audit Opinions
--
--
--
--
--
--
--
--
Unqualified Opinion
--
(Q3)Sep 30, 2024(Q2)Jun 30, 2024(Q1)Mar 31, 2024(FY)Dec 31, 2023(Q4)Dec 31, 2023(Q3)Sep 30, 2023(Q2)Jun 30, 2023(Q1)Mar 31, 2023(FY)Dec 31, 2022(Q4)Dec 31, 2022
Total revenue 00084,762.39%370M3,333,233.33%200M044,203.80%70M56,079.78%100M-99.95%436K-99.95%6K
Operating revenue --0--0--084,762.39%370M3,333,233.33%200M--044,203.80%70M56,079.78%100M-99.95%436K-99.95%6K
Cost of revenue -52.38%11.15M16.79%52.13M11.31%46.97M18.14%130.25M193.13%20M-39.73%23.42M31.58%44.64M37.68%42.19M8.97%110.25M-78.56%6.82M
Gross profit 52.38%-11.15M-305.53%-52.13M-181.24%-46.97M318.32%239.75M2,740.46%180M39.58%-23.42M175.12%25.36M289.73%57.81M-113.53%-109.81M65.00%-6.82M
Operating expense -9.19%98.98M-17.79%99.13M-23.45%93.62M-17.94%462.29M-11.47%110.42M-24.11%108.99M-19.34%120.59M-15.95%122.3M28.51%563.35M-1.19%124.72M
Selling and administrative expenses -4.77%17.42M2.36%19.48M-19.71%17.95M-25.67%76.16M-22.16%16.48M-32.26%18.29M-27.56%19.03M-20.20%22.36M2.78%102.46M-10.60%21.17M
-General and administrative expense -4.77%17.42M2.36%19.48M-19.71%17.95M-25.67%76.16M-22.16%16.48M-32.26%18.29M-27.56%19.03M-20.20%22.36M2.78%102.46M-10.60%21.17M
Research and development costs -9.41%82.16M-21.06%80.17M-23.78%76.17M-16.10%387.33M-8.12%95.14M-22.23%90.7M-17.58%101.56M-15.48%99.94M35.55%461.65M0.45%103.56M
Other operating expenses ---602K---517K---504K-58.27%-1.21M----------------59.51%-762K--0
Operating profit 16.83%-110.13M-58.85%-151.26M-118.01%-140.59M66.94%-222.54M152.90%69.58M27.40%-132.41M48.04%-95.22M63.35%-64.49M-280.22%-673.16M9.72%-131.54M
Net non-operating interest income expense
Other net income (expense) 21.25%25.06M42.01%26.14M94.00%24.72M216.91%71.82M74.04%20M184.57%20.67M419.36%18.41M3,410.19%12.74M277.49%22.66M422.99%11.49M
Other non- operating income (expenses) 21.25%25.06M42.01%26.14M94.00%24.72M216.91%71.82M74.04%20M184.57%20.67M419.36%18.41M3,410.19%12.74M277.49%22.66M422.99%11.49M
Income before tax 23.87%-85.07M-62.88%-125.12M-123.92%-115.87M76.83%-150.72M174.62%89.58M36.19%-111.74M57.26%-76.82M70.53%-51.75M-271.40%-650.5M16.34%-120.05M
Income tax 112.62%876K39.44%1.29M-45.15%724K988.62%2.89M102.46%233K171.65%412K-84.91%923K-63.41%1.32M-117.38%-325K-320.59%-9.48M
Net income 23.37%-85.94M-62.60%-126.41M-119.71%-116.59M76.37%-153.61M180.80%89.35M35.75%-112.15M58.17%-77.74M70.39%-53.07M-272.16%-650.18M21.72%-110.58M
Net income continuous Operations 23.37%-85.94M-62.60%-126.41M-119.71%-116.59M76.37%-153.61M180.80%89.35M35.75%-112.15M58.17%-77.74M70.39%-53.07M-272.16%-650.18M21.72%-110.58M
Minority interest income
Net income attributable to the parent company 23.37%-85.94M-62.60%-126.41M-119.71%-116.59M76.37%-153.61M180.80%89.35M35.75%-112.15M58.17%-77.74M70.39%-53.07M-272.16%-650.18M21.72%-110.58M
Preferred stock dividends
Other preferred stock dividends
Net income attributable to common stockholders 23.37%-85.94M-62.60%-126.41M-119.71%-116.59M76.37%-153.61M180.80%89.35M35.75%-112.15M58.17%-77.74M70.39%-53.07M-272.16%-650.18M21.72%-110.58M
Basic earnings per share 28.37%-1.01-52.04%-1.49-113.43%-1.4376.79%-1.94180.14%1.1337.05%-1.4159.17%-0.9871.12%-0.67-268.21%-8.3623.37%-1.41
Diluted earnings per share 28.37%-1.01-52.04%-1.49-113.43%-1.4376.79%-1.94180.14%1.1337.05%-1.4159.17%-0.9871.12%-0.67-277.87%-8.3623.37%-1.41
Dividend per share
Currency Unit USDUSDUSDUSDUSDUSDUSDUSDUSDUSD
Accounting Standards US-GAAPUS-GAAPUS-GAAPUS-GAAPUS-GAAPUS-GAAPUS-GAAPUS-GAAPUS-GAAPUS-GAAP
Audit Opinions ----------------Unqualified Opinion--
Trending US Stocks
Fed Rate Cut Beneficiaries Fed Rate Cut Beneficiaries

Stocks that are expected to benefit from a Federal Reserve rate cut. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only. This section presents the top 5 stocks in Fed Rate Cut Beneficiaries, ranked from highest to lowest based on real-time market data. Stocks that are expected to benefit from a Federal Reserve rate cut. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only. This section presents the top 5 stocks in Fed Rate Cut Beneficiaries, ranked from highest to lowest based on real-time market data.

Symbol Mini Chart % Chg
Alphabet-A
GOOGL
+5.59%
Alphabet-C
GOOG
+5.32%
MicroStrategy
MSTR
+3.28%
Tesla
TSLA
+2.87%
Ecopetrol
EC
+1.83%

Unlock the Full List

Investment Theme ARK Portfolio
ARK Portfolio
Intraday+1.23%
Gene Editing
Gene Editing
Intraday-1.00%